Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Sepsis Diagnostics Market, by Product Type (Blood Culture Media, Assays & Reagents, Instruments, and Software), by Method (Automated Diagnostics and Conventional Diagnostics), by Pathogen (Bacterial Sepsis {Gram-Negative Bacterial Sepsis and Gram-Positive Bacterial Sepsis}, Fungal Sepsis, and Others), by Technology (Microbiology, Molecular Diagnostics, Immunoassays, and Flow Cytometry), by End User (Hospitals, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 702.2 million in 2021, and is expected to exhibit a CAGR of 9.6% during the forecast period (2021-2028).

Rising cases of hospital acquired infections is expected to drive growth of the global sepsis diagnostics market during the forecast period. For instance, according to the Centers for disease control and prevention (CDC) data, in the U.S., there was an increase of 2% in the incidences of ventilator associated infections in 2019 as compared to 2018. Moreover, according to 2018 Annual Report for the Emerging Infections Program by CDC, more than 15,000 cases of Clostridium difficile infection (CDI), a hospital acquired infection were reported across 10 states in the U.S.

Market players are engaged in inorganic activities such as acquisitions, partnerships, and others. For instance, in February 2020, Curetis AG, a German molecular diagnostic company entered into partnership with Quaphaco, a Vietnam based medical equipment supplier for distribution of its product Unyvero for detection of lower respiratory tract infections such as pneumonia. Moreover, in 2019, Curetis AG received the U.S. Food and Administration 510k clearance for Unyvero. Pneumonia is one of the causes of sepsis, thus adoption of market strategies for distribution of such diagnostic systems is expected to drive the growth of global sepsis diagnostics market over the forecast period.

Global Viral Conjunctivitis Drugs Market - Impact of Coronavirus (COVID – 19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. For instance, according to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 180 million cases and 3.9 million deaths due to Coronavirus (COVID-19) were reported up till June 27, 2021 across the globe.

COVID-19 pandemic is expected to boost the market growth of sepsis diagnostics due to growing number of cases of COVID-19 and need for early detection of sepsis associated with COVID-19 infection. Moreover, according to the Global Sepsis Alliance data 2020, around 2-5% patients suffering from severe COVID-19 infection show symptoms of sepsis such as multi-organ damage within 8-10 days of hospitalization. Furthermore, according to the Canadian Medical Association data 2020, sepsis is one of the most common complication associated with COVID-19 and it is estimated that the risk of acquiring COVID-19 associated sepsis is 10.4%. Hence, researchers are carrying out intensive studies to develop efficient molecular diagnostic tools for detection of sepsis and COVID-19.

Browse 37 Market Data Tables and 26 Figures spread through 168 Pages and in-depth TOC on Global Sepsis Diagnostics Market, by Product Type (Blood Culture Media, Assays & Reagents, Instruments, and Software), by Method (Automated Diagnostics and Conventional Diagnostics), by Pathogen (Bacterial Sepsis {Gram-Negative Bacterial Sepsis and Gram-Positive Bacterial Sepsis}, Fungal Sepsis, and Others), by Technology (Microbiology, Molecular Diagnostics, Immunoassays, and Flow Cytometry), by End User (Hospitals, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the Global Sepsis Diagnostics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/sepsis-diagnostic-market-1166

Moreover, launch of new products and regulatory approvals is expected to drive the global sepsis diagnostics market growth. For instance, in May 2018, T2 Biosystems, Inc., a U.S. based in vitro-diagnostic company, received the U.S. FDA approval for its new product T2Bacteria Panel which is used for detection of sepsis causing bacteria in blood samples.

Key Takeaways of the Sepsis Diagnostics Market:

  • The global sepsis diagnostics market is expected to exhibit a CAGR of 9.6% over the forecast period (2021-2028). North America region is expected to account for major market share over the forecast period (2021-2028) owing rising number of product launches. For instance, in May 2020, Beckman Coulter, a U.S. based biomedical testing solutions provider launched its new product DxH 690T hematology analyzer which can be used for early detection of sepsis.
  • Some of the major players operating in the global sepsis diagnostics market include BioMérieux SA, Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics AG, Luminex Corporation, CytoSorbents Corporation, Becton Dickinson Company, Danaher Corporation, Axis-Shield Diagnostics, T2 Biosystems, EKF Diagnostics, Immunexpress Inc., Response Biomedical Corporation, and Bruker Corporation
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.